Options traders are blasting pharma stock AstraZeneca PLC (NASDAQ:AZN) today, after the U.S. Food and Drug Administration (FDA) failed to find any safety issues with the company's experimental respiratory syncytial virus (RSV) therapy for infections in infants.
According to FDA staff in documents published ahead of the Thursday committee meeting to discuss the therapy's marketing application, "the RSV prevention antibody, nirsevimab, showed an overall favorable safety profile in clinical trials."
So far, 51,000 calls and 13,000 puts have been exchanged, volume that's roughly five times the average intraday amount. The July 75 call is the most popular, with new positions being opened bought to open. The second-most active contract, the June 72.50 call, is the most popular short interest position by far.
AZN is flat today, last seen trading at $73.26. The stock isn't far off its April 25 record high of $76.56, but remains only up 8% year-to-date.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
